Serum vedolizumab and corresponding anti-vedolizumab antibody: Analysis of over 6500 patient results using lab developed chemiluminescent immunoassays (ECLIA)

Serum ustekinumab and corresponding anti-ustekinumab antibody: Analysis of over 2000 patient results using lab developed chemiluminescent immunoassays (ECLIA)

Pro-inflammatory small LDL-like particles in patients with severe liver disease

Characterization of LP-Z abnormal lipoprotein particles and quantification in subjects with liver disease